MRM Health NV has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration to initiate the STARFISH-UC Phase 2b trial for MH002, its oral live microbial consortium candidate for mild-to-moderate ulcerative colitis. The approval positions the Belgium-based clinical-stage biopharmaceutical company to launch the largest trial to date for what is currently the most advanced live biotherapeutic product (LBP) designed for inflammatory bowel diseases.

Why MH002’s entry into phase 2b reveals confidence in live microbial consortia for IBD

The FDA’s IND clearance for MH002 is more than a procedural milestone. It signifies growing regulatory recognition of rationally designed microbial therapeutics as credible contenders in immunology and inflammatory indications. While the broader field of microbiome-based therapies has endured cycles of hype and setbacks, MH002’s ability to move from phase 2a signals into a well-powered, multinational phase 2b study suggests its early results were both clinically meaningful and manufacturable at scale.

MH002’s structure—a six-strain microbial consortium designed for synergistic action—reflects a shift from single-strain probiotics toward rationally composed therapeutics that target disease biology directly. Unlike fecal microbiota transplants or broad-spectrum microbial cocktails, MH002 is built using the company’s proprietary CORAL platform, which allows for reproducible manufacturing of full consortia as a single drug substance. This design choice could remove several translational bottlenecks that have historically hindered microbiome therapeutics from reaching late-stage trials or commercialization.

For ulcerative colitis—a relapsing-remitting autoimmune condition of the colon—the dominant therapeutic options are still 5-aminosalicylates, corticosteroids, immunomodulators, and biologics such as TNF inhibitors. Each comes with tolerability, efficacy durability, and safety trade-offs. A safe, immune-sparing oral option that restores mucosal health via microbial mechanisms could fill a major unmet need, especially for patients inadequately controlled by first-line therapies but not yet eligible for advanced biologics.

What the STARFISH-UC trial structure tells us about MH002’s regulatory and commercial ambitions

The STARFISH-UC trial (NCT07296315) is carefully designed to validate the initial phase 2a signal in a statistically robust setting. The randomized, double-blind, placebo-controlled design will enroll approximately 204 patients with mild-to-moderate ulcerative colitis who remain symptomatic despite treatment with 5-aminosalicylates (with or without low-dose steroids). The trial includes a 12-week induction phase with two dosing arms, followed by a 40-week open-label extension, ensuring long-term safety and durability data.

The trial’s structure—spanning both the U.S. and Europe—also reflects a strategy aimed at aligning with both FDA and EMA regulatory expectations, laying the groundwork for subsequent pivotal trials. Enrollment is expected to begin by mid-2026, which could allow for topline induction data by late 2027 or early 2028, depending on recruitment pace and data maturity.

This timeline aligns with the current investment cycle for MRM Health, which closed a €55 million Series B round in September 2025. That funding round, led by Biocodex and supported by BNP Paribas Fortis Private Equity, Athos, SFPIM, and others, appears explicitly structured to support MH002 through this critical trial phase.

How MH002 compares with existing and emerging ulcerative colitis treatment options

MH002’s competitive positioning hinges on three interrelated claims: mucosal healing, microbiome restoration, and immune system sparing. In the earlier phase 2a study, MH002 demonstrated strong safety and early efficacy signals, including remission and anti-inflammatory effects, in just eight weeks. A follow-up open-label study in acute pouchitis also showed potential utility beyond ulcerative colitis.

Compared to existing biologics like infliximab, vedolizumab, or ustekinumab—which target systemic inflammatory pathways—MH002 offers a mechanistically distinct, gut-localized approach. If the STARFISH-UC trial replicates its early signals, MH002 could appeal to both newly diagnosed patients and those looking to delay immunosuppression or avoid infusion-based regimens.

However, it will need to outperform more than biologics. Next-generation oral therapies, including S1P modulators like ozanimod and JAK inhibitors such as tofacitinib, have started competing for the same patient segments. These small molecules offer convenient oral delivery, fast onset, and in some cases, steroid-sparing effects—but also carry black-box warnings or require monitoring.

MH002’s safety profile could become a differentiator—if confirmed in the larger trial—particularly for early-stage patients and pediatric use. But unlike molecules with defined pharmacokinetics, live biotherapeutics face added complexity around colonization dynamics, dietary interactions, and host-microbe variability, which can impact both trial outcomes and eventual prescriber adoption.

Why the CORAL platform may become a differentiator in the LBP field

Live biotherapeutics have long been plagued by manufacturing inconsistencies, strain survival issues, and regulatory ambiguity. MRM Health claims to have solved part of this problem through its CORAL® platform, which enables the streamlined design and cGMP production of microbial consortia as a single drug substance.

This capability is non-trivial. Many LBP developers must manufacture individual strains separately and then combine them—a process fraught with quality control hurdles and scale limitations. CORAL’s one-step process could offer a cost-effective and reproducible path to commercialization, reducing batch variability and supporting global supply chain scalability.

If MH002 reaches approval, MRM Health may gain a second-mover advantage in live consortia therapeutics, trailing only trailblazers like Seres Therapeutics or Rebiotix, but with arguably greater platform depth. The ability to manufacture a six-strain consortium at scale could also unlock future programs beyond ulcerative colitis, including systemic inflammatory diseases and immuno-oncology, where microbiome modulation is being increasingly explored.

What industry observers are watching as MRM Health scales into pivotal territory

As MRM Health enters phase 2b territory, the field is watching for several inflection points. First, the STARFISH-UC trial’s recruitment and retention rates will be closely watched, especially given that mild-to-moderate patients often cycle through multiple therapies before enrolling in trials. Second, MH002’s signal consistency across global sites will be scrutinized, given regional microbiome variations and standard-of-care heterogeneity.

Third, and perhaps most importantly, observers will watch whether MH002 can demonstrate long-term microbiome restoration without triggering unintended immune effects or colonization resistance. These questions are critical not just for regulators, but for payers—who will require both clear benefit over existing therapies and predictable manufacturing to justify reimbursement.

Finally, the broader question remains whether live microbial therapeutics can truly reach first-line or combination therapy status—or whether they will remain niche adjuncts to more potent agents. The STARFISH-UC trial will begin to answer this, but only a successful phase 3 program will settle the question.

  clinical trial, CORAL platform, FDA IND, Inflammatory Bowel Disease, live biotherapeutic product, MH002, microbiome, MRM Health, STARFISH-UC, ulcerative colitis